Leverage Lunit’s proven AI technology and domain expertise to unlock transformative insights for patient stratification, derisking, and accelerating clinical trials or streamlining target identification.
Our portfolio of purpose-built solutions—Lunit SCOPE IHC Suite, SCOPE IO, and SCOPE GP—are designed to support biomarker-driven strategies for advancing emerging drug programs including antibody-drug conjugates, immuno-oncology therapies, or targeted small molecules.
Our AI models generate extensive data, and our internal biomedical research team and medical directors help navigate it to identify the most relevant data points to answer your scientific questions.
With an internal team of over 20 medical doctors and 50 AI researchers, Lunit is dedicated to developing clinically impactful AI solutions. Over the past 12 years, our cancer screening technologies have been adopted by more than 10,000 healthcare providers across 65+ countries, supporting confident clinical decisions every day.
They tell me: you’re finding the smallest
cancers we didn’t see before.
It’s making a real difference.” These successes have strengthened trust, increased referrals to their center, and directly benefited patients. Smaller cancers often mean less invasive treatment, lower costs, and better prognoses.
This collaboration with Lunit underscores our commitment to advancing precision medicine in oncology. Tools like this will help to address unmet needs by optimizing diagnostic workflows for NSCLC patients and, ultimately, improve their outcomes.
Restez informé des dernières avancées de la recherche, des nouveautés produits et des partenariats internationaux qui stimulent l'innovation dans le domaine de l'oncologie de précision basée sur l'IA.
